{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:50:35Z","timestamp":1771876235469,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Objective<\/jats:title>\n To investigate the specific tumor survival situation of cytoreductive prostatectomy for prostate cancer with lung metastasis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Case data of prostate cancer patients diagnosed from 2010 to 2015 were collected from the SEER database (\n https:\/\/seer.cancer.gov\/<\/jats:ext-link>\n ) to obtain age, race, marital status, T stage, N stage, ISUP grade, prostate-specific antigen level (PSA), surgery, radiotherapy, chemotherapy, and survival time. The subjects were divided into surgical groups (CDS): resection of the primary lesion (prostate) and non-surgical groups (NCDS). The purpose of palliative debulking is to reduce the tumor burden. Only the primary lesion of the prostate is removed, while metastatic lesions are not subjected to surgical resection. Propensity score matching (PSM) was used to control confounding factors, and the survival outcomes of the two groups were systematically evaluated. Kaplan-Meier survival curves and forest plots were plotted to further verify the survival benefits of the surgery.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 808,782 cases were screened through the SEER database, and ultimately 1548 cases were eligible for prostate cancer with lung metastasis, including 136 cases in the surgical group and 1412 cases in the non-surgical group. After PSM, there were 70 cases in the surgical group and 70 cases in the non-surgical group. The Kaplan-Meier survival curve showed no survival difference between the two groups, P\u2009=\u20090.28, and the forest plot further confirmed no survival difference between the two groups. The Kaplan-Meier survival curve analysis for the subgroups that received further radiotherapy and chemotherapy showed that there was no statistically significant difference in the tumor-specific survival time among the subgroups (P\u2009>\u20090.05).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Cytoreductive prostatectomy does not prolong the specific tumor survival time of prostate cancer patients with lung metastasis, Radiotherapy and chemotherapy also fail to extend the specific tumor survival time for these patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0342758","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:48:20Z","timestamp":1771872500000},"page":"e0342758","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival study of cytoreductive prostatectomy for prostate cancer with lung metastasis: A propensity score matching study based on the SEER database"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-2914","authenticated-orcid":true,"given":"An-Ping","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Feng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Qian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"3","key":"pone.0342758.ref001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"pone.0342758.ref002","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"N Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"pone.0342758.ref003","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.ctrv.2024.102726","article-title":"First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States","volume":"126","author":"RR McKay","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"pone.0342758.ref004","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"RL Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"pone.0342758.ref005","article-title":"Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients","volume":"19","author":"G-S Lai","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"pone.0342758.ref006","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/JU.0000000000003594","article-title":"Efficacy of systemic treatment in prostate cancer patients with visceral metastasis: a systematic review, meta-analysis, and network meta-analysis","volume":"210","author":"T Yanagisawa","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"pone.0342758.ref007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5334\/jbsr.3008","article-title":"Cavitary lung metastases in prostate cancer","volume":"106","author":"F Delbare","year":"2022","journal-title":"J Belg Soc Radiol"},{"issue":"1","key":"pone.0342758.ref008","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41391-022-00605-7","article-title":"Incidence and survival of castration-resistant prostate cancer patients with visceral metastases: results from the Dutch CAPRI-registry","volume":"26","author":"GPA van den Bergh","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"pone.0342758.ref009","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5306\/wjco.v14.i10.420","article-title":"What should be the future direction of development in the field of prostate cancer with lung metastasis?","volume":"14","author":"Z-G Huang","year":"2023","journal-title":"World J Clin Oncol"},{"issue":"11","key":"pone.0342758.ref010","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3390\/cancers16112080","article-title":"Prostate cancer lung metastasis: clinical insights and therapeutic strategies","volume":"16","author":"AM Mahmoud","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0342758.ref011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"PC Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"18","key":"pone.0342758.ref012","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.3390\/cancers16183224","article-title":"Risk of esophageal and gastric cancer in patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis","volume":"16","author":"M Ayoub","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0342758.ref013","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/cam4.5142","article-title":"Survival benefits of primary tumor surgery for synchronous brain metastases: a SEER-based population study with propensity-matched comparative analysis","volume":"12","author":"C Zhang","year":"2023","journal-title":"Cancer Med"},{"issue":"17","key":"pone.0342758.ref014","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"M Sekhoacha","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"pone.0342758.ref015","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"F Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"pone.0342758.ref016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/CMAR.S495169","article-title":"Prostate cancer bone metastasis: molecular mechanisms of tumor and bone microenvironment","volume":"17","author":"H Jiang","year":"2025","journal-title":"Cancer Manag Res"},{"issue":"5","key":"pone.0342758.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323180","article-title":"Predicting prostate cancer metastasis in Ghana: comparison of multiparametric and PSA models","volume":"20","author":"F Obeng","year":"2025","journal-title":"PLoS One"},{"issue":"4","key":"pone.0342758.ref018","doi-asserted-by":"crossref","first-page":"405","DOI":"10.21873\/cgp.20459","article-title":"CEACAM6 promotes lung metastasis via enhancing proliferation, migration and suppressing apoptosis of prostate cancer cells","volume":"21","author":"A Saraji","year":"2024","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"pone.0342758.ref019","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000512825","article-title":"Solitary lung metastasis of prostate cancer with a long disease-free interval and normal prostate-specific antigen level","volume":"14","author":"H Yoshitake","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"1","key":"pone.0342758.ref020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13062-024-00494-x","article-title":"Identification of metastasis-related genes for predicting prostate cancer diagnosis, metastasis and immunotherapy drug candidates using machine learning approaches","volume":"19","author":"Y Wang","year":"2024","journal-title":"Biol Direct"},{"issue":"3","key":"pone.0342758.ref021","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737159.2023.2187289","article-title":"Molecular predictors of metastasis in patients with prostate cancer","volume":"23","author":"J Lin","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"issue":"41","key":"pone.0342758.ref022","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"DA Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"pone.0342758.ref023","article-title":"Application of a novel machine learning framework for predicting non-metastatic prostate cancer-specific mortality in men using the Surveillance, Epidemiology, and End Results (SEER) database","volume":"3","author":"C Lee","year":"2021","journal-title":"Lancet Digit Health"},{"issue":"16","key":"pone.0342758.ref024","doi-asserted-by":"crossref","first-page":"16697","DOI":"10.1002\/cam4.6292","article-title":"The role of cytoreductive radical prostatectomy and lymph node dissection in bone-metastatic prostate cancer: a population-based study","volume":"12","author":"T Zhai","year":"2023","journal-title":"Cancer Med"},{"key":"pone.0342758.ref025","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12935-020-01583-3","article-title":"Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity","volume":"20","author":"J Zhu","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"23","key":"pone.0342758.ref026","article-title":"SMC4 promotes prostate cancer cell proliferation and metastasis via the Rheb\/mTOR Pathway","volume":"12","author":"W Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"pone.0342758.ref027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00120-024-02285-8","article-title":"Palliative surgery for metastatic prostate cancer","volume":"63","author":"A Heidenreich","year":"2024","journal-title":"Urologie"},{"key":"pone.0342758.ref028","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2021.02.011","article-title":"Survival after palliative radiation therapy for cancer: The METSSS model","volume":"158","author":"NG Zaorsky","year":"2021","journal-title":"Radiother Oncol"},{"issue":"2","key":"pone.0342758.ref029","first-page":"139","article-title":"Palliative urologic surgery for metastatic prostate cancer: what needs to be considered in the future?","volume":"55","author":"A Heidenreich","year":"2024","journal-title":"Aktuelle Urol"},{"issue":"6","key":"pone.0342758.ref030","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1097\/MS9.0000000000003204","article-title":"Isolated lung metastasis prostate cancer","volume":"87","author":"E Mduma","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"5","key":"pone.0342758.ref031","first-page":"004494","article-title":"Atypical pulmonary metastasis of prostate adenocarcinoma: a rare phenomenon","volume":"11","author":"A Jamil","year":"2024","journal-title":"Eur J Case Rep Intern Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:48:26Z","timestamp":1771872506000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342758"}},"subtitle":[],"editor":[{"given":"Li","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342758","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]}}}